StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck invanz (ertapenem, legacy) — International reported growth YoY (%) (%)

Form 8-K Table 3a / 3b Product Sales

QuarterlyAnnual
Latest, Q3 2022
-14.0%
Period ended Sep 30, 2022
Change on a year earlier
-26.0 pts
12.0% in Q3 2021
History
16 quarters
Since Q4 2017
Sources
16
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedInvanz (ertapenem, legacy) — International reported growth YoY (%) (%)Year on yearSource
Q3 2022Sep 30, 2022-14.0%-26.0 ptsForm 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 2022-13.0%–Form 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 2022-2.0%+9.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 2021-5.0%–Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2021Sep 30, 202112.0%+26.0 ptsForm 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗
Q1 2021Mar 31, 2021-11.0%-12.0 ptsForm 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q3 2020Sep 30, 2020-14.0%-7.0 ptsForm 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q1 2020Mar 31, 20201.0%+5.0 ptsForm 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q3 2019Sep 30, 2019-7.0%-1.0 ptsForm 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗
Q2 2019Jun 30, 2019-3.0%-12.0 ptsForm 8-K (a19-15283_1ex99d1.htm, filed 2019-07-30) ↗
Q1 2019Mar 31, 2019-4.0%-15.0 ptsForm 8-K (a19-8996_1ex99d1.htm, filed 2019-04-30) ↗
Q4 2018Dec 31, 2018-8.0%-10.0 ptsForm 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2018Sep 30, 2018-6.0%–Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗
Q2 2018Jun 30, 20189.0%–Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗
Q1 2018Mar 31, 201811.0%–Form 8-K (a18-12417_1ex99d1.htm, filed 2018-05-01) ↗
Q4 2017Dec 31, 20172.0%–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Cite this data

StockData. (2026). Merck Invanz (ertapenem, legacy) — International reported growth YoY (%) (%), quarterly Q4 2017–Q3 2022 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_invanz_intl_nom_yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.